Key Takeaways (4-6 bullets, will render as highlighted box)
- The Novo Nordisk Wegovy savings offer lets eligible commercially insured patients pay as little as $25 per fill, with a maximum savings of $100 per 1-month fill ($200 per 2-month, $300 per 3-month), per NovoCare's terms read September 4, 2026.
- Government-insured patients (Medicare, Medicaid, TRICARE, VA) are excluded from the savings card. This is a federal anti-kickback law restriction, not a Novo Nordisk choice.
- The card only reduces copays. It does not provide coverage. If your plan does not cover Wegovy at all, the savings card cannot help.
- Cash-pay patients (no insurance) cannot use the savings card directly but can sometimes access Novo Nordisk's discounted cash-pay program, $199 a month for the first two pen fills (new patients, through December 31, 2026) then $349, $399 for Wegovy HD, and $149 to $299 for the Wegovy pill.
- Uninsured patients with household income at or below 400% of the federal poverty level ($63,840 for one person, $132,000 for a family of four in 2026) may qualify for the Novo Nordisk Patient Assistance Program; confirm Wegovy is on the current PAP product list before applying.
The short answer
The Wegovy manufacturer coupon, called the Wegovy Savings Offer by Novo Nordisk, lets eligible commercially insured patients pay as little as $25 per fill, with Novo covering up to $100 a month. Patients on Medicare, Medicaid, TRICARE, or any government plan are excluded from the card, though since July 1, 2026 eligible Medicare patients pay $50 a month through the Medicare GLP-1 Bridge. Novo's current terms publish per-fill caps, not a months-of-use limit.
Table of contents
- The 30-second answer
- What the Wegovy savings card is and isn't
- Who qualifies (and who doesn't)
- What it actually saves: real scenarios
- How to get and use the card
- Why government-insured patients can't use it
- The cash-pay program: NovoCare direct pricing
- Patient assistance program for low-income patients
- What to do if you don't qualify for any program
- 2026 savings offer terms
- Coupon vs self-pay
- Medicare: the $50 GLP-1 Bridge
- PAP income limits, 2026
- January 2027: $675 list price
- FAQ
- Sources
- Footer disclaimers
What the Wegovy savings card is and isn't
The Wegovy savings card is a manufacturer copay assistance program from Novo Nordisk. It reduces the out-of-pocket cost for commercially insured patients whose insurance covers Wegovy.
See transparent compounded pricing
Review compounded GLP-1 pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →What it is:
- A copay reduction tool for patients with commercial insurance that covers Wegovy
- Subject to per-fill savings caps set in the current program terms, which Novo can change
- A way to bring a copay of up to $125 down to $25, and to cut higher copays by $100
- Distributed by Novo Nordisk through its NovoCare program
What it isn't:
- Insurance. The card doesn't cover anything. It only reduces what your insurance already lets you owe.
- Useful for the uninsured. If you have no insurance, the card has no copay to reduce.
- Available to government-insured patients. Medicare, Medicaid, TRICARE, and VA patients are excluded by federal law.
- A way around prior authorization. Your insurance still has to approve coverage first.
The most common confusion: patients assume the card is a coupon they can redeem for $199 or $349 Wegovy regardless of insurance. It isn't. The card is a benefit layered on top of existing coverage.
Who qualifies (and who doesn't)
Eligible:
- Adults 18+
- U.S. residents
- Have commercial (private, employer, or marketplace) prescription drug coverage that includes Wegovy
- Have a valid prescription for Wegovy from a U.S.-licensed clinician
- Diagnosis aligns with Wegovy's FDA-approved use (BMI 30+ or BMI 27+ with one weight-related comorbidity)
Not eligible:
- Anyone enrolled in Medicare (Part D, Medicare Advantage, or any Medicare drug plan)
- Anyone enrolled in Medicaid or any state-funded health program
- Anyone enrolled in TRICARE, the VA, or another federal program
- Anyone uninsured
- Anyone whose commercial plan does not cover Wegovy at all
- Patients in any state where the program is restricted by state law
The rule about government-insured patients is not a Novo Nordisk preference. The federal anti-kickback statute prohibits manufacturers from offering copay assistance to patients whose drugs are paid for by federal programs. Violators face civil penalties and exclusion from federal healthcare programs (HHS OIG advisory opinions on copay assistance programs).
What it actually saves: real scenarios
The Wegovy savings card has tiered benefits depending on whether your plan covers Wegovy and how much your copay is.
Scenario 1: Commercial plan covers Wegovy with low copay.
- Plan copay: $50 per fill
- Savings card brings copay to: $25 (Novo pays the other $25)
- Out of pocket: $25 per month
Scenario 2: Commercial plan covers Wegovy with high copay.
- Plan copay: $400 per fill
- Savings card maximum benefit: $100 per 1-month fill
- Out of pocket: $300 per month after the card, which is why Novo's $349 self-pay pen price is worth comparing
Scenario 3: Commercial plan does not cover Wegovy.
- Wegovy is not on formulary
- Savings card cannot help (no copay to reduce)
- Out of pocket: Novo's self-pay price ($199 for the first two pen fills, then $349; pill $149 to $299) rather than the roughly $1,643 retail figure
Scenario 4: High-deductible plan, deductible not met.
- Pre-deductible cost: the plan's negotiated rate, close to the $1,349.02 list price
- Savings card maximum: $100, not enough to bring the price close to $25
- Out of pocket: still hundreds per fill until deductible is met
Scenario 5: Medicare patient.
- Plan copay: $400 per fill (typical specialty tier)
- Savings card: not allowed
- Out of pocket: $50 a month through the Medicare GLP-1 Bridge if the patient meets CMS criteria (July 1, 2026 to December 31, 2027); otherwise the plan's copay up to the 2026 Part D cap of $2,100
The pattern: the savings card is best for patients with covered Wegovy and moderate copays. It's of limited help for patients with no coverage, high deductibles unmet, or government insurance.
How to get and use the card
Step 1: Confirm Wegovy is covered by your plan. Call your insurance member services or check your plan's online formulary. Search for "semaglutide 2.4 mg" or "Wegovy." Note the tier and whether prior authorization is required.
Step 2: Get a Wegovy prescription. Through your primary care doctor, an obesity medicine specialist, or a licensed telehealth platform. The prescriber will submit prior authorization if your plan requires it.
Step 3: Download the savings card. Visit the NovoCare website (NovoCare.com/Wegovy) or the dedicated savings card page. You'll fill in basic information (name, ZIP code, insurance status) and receive a digital savings card you can print or save to your phone.
Step 4: Bring both your insurance card and the savings card to the pharmacy. The pharmacist runs your insurance first, calculates your copay, then applies the savings card. Most major pharmacy chains process the savings card directly through their system; some require you to provide the BIN, PCN, group, and member ID printed on the card.
Step 5: Keep records. The savings card's limit is per fill ($100, $200 or $300 for a 1-, 2- or 3-month prescription). If your copay is above $125 you will pay the excess every month, so compare the result against Novo's self-pay price.
If the pharmacist says the card "isn't going through," the most common causes are: government insurance involvement (the card is being correctly rejected), prior authorization not approved, or pharmacy data not yet updated. Call the NovoCare helpline (printed on the card) to troubleshoot.
Why government-insured patients can't use it
This is the most asked question about manufacturer coupons in general.
The legal reason: The federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)) prohibits drug manufacturers from offering anything of value to induce the prescribing or purchase of a drug paid for by a federal health program. The HHS Office of Inspector General has interpreted manufacturer copay coupons as inducements (HHS OIG, multiple advisory opinions).
If a manufacturer offers a coupon to a Medicare patient, both the manufacturer and the patient may be subject to enforcement action. The manufacturer can face civil penalties and exclusion from Medicare; the patient could be required to repay any covered amount.
Practical implication: Pharmacies are required to identify when a patient is on a government plan and reject the coupon at the point of sale. This is a legal requirement, not a customer-service decision.
Workarounds for government-insured patients:
- Apply for the Novo Nordisk Patient Assistance Program (income-based)
- Use Medicare's Extra Help program if low-income
- Apply for the Medicare GLP-1 Bridge: $50 a month for any Wegovy pen or pill strength, July 1, 2026 to December 31, 2027, prior authorization required
- For Medicaid patients, check the state's preferred drug list and prior authorization process
- Pivot to compounded semaglutide, which Medicare does not cover but where cash pricing can be lower
The cash-pay program: NovoCare direct pricing
Novo Nordisk sells Wegovy directly to self-pay patients through NovoCare Pharmacy and, via GoodRx, at retail pharmacies. Pricing has shifted more than once. As of September 4, 2026: pen $199 a month for the first two fills (new patients, through December 31, 2026) then $349 for every dose from 0.25 mg to 2.4 mg; Wegovy HD 7.2 mg $399; Wegovy pill $149 (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg).
Who it's for:
- Patients with no insurance
- Patients whose insurance does not cover Wegovy at all
- Patients who prefer to skip the prior authorization process
How it works:
- Visit NovoCare.com/wegovy
- Enroll, share prescription information
- Wegovy ships from a Novo Nordisk-partnered pharmacy
- Pay direct to the pharmacy at the discounted price
Limitations:
- Cannot be combined with insurance
- Cannot be combined with the savings card
- Pricing is subject to change (Novo Nordisk has adjusted the cash price more than once since launch)
Comparison:
| Path | Approximate monthly cost |
|---|---|
| Wegovy with strong commercial coverage and savings card | $25 |
| Wegovy with moderate commercial coverage and savings card | Copay minus $100 (a $250 copay becomes $150) |
| Wegovy with weak coverage / high deductible | Up to the full negotiated rate (near the $1,349 list price) inside the deductible |
| Wegovy with Novo self-pay program | $199 first two pen fills, then $349; HD $399; pill $149 to $299 |
| Brand-name Wegovy retail (no insurance, no programs) | About $1,643 (GoodRx average retail, September 2026) |
| Compounded semaglutide (FormBlends) | Current price on the product page and in our price index; September 2026 market median $197 for month 1 |
| Patient Assistance Program (income-eligible) | $0 |
For uninsured patients the gap has narrowed: the Wegovy pill at $149 a month now sits below the September 2026 compounded semaglutide median of $197, while the pen at $349 sits above it. Compounded semaglutide is not interchangeable with Wegovy.
Patient assistance program for low-income patients
Novo Nordisk's Patient Assistance Program (PAP) provides Novo medicines at no cost to patients who meet income criteria. NovoCare's 2026 PAP page states the eligibility rules but did not list Wegovy by name when we read it on September 4, 2026, so confirm Wegovy is on the current product list before applying.
Eligibility (as of 2026):
- Household income at or below 400% of the federal poverty level ($63,840 for one person, $86,560 for two, $132,000 for a family of four under the 2026 HHS guidelines)
- U.S. resident or legal U.S. resident
- No prescription drug coverage (or coverage that does not cover Wegovy)
- Valid prescription from a U.S.-licensed clinician
What it provides:
- Wegovy free for up to 12 months at a time, renewable
- Shipped directly from Novo Nordisk to the patient
- No copay, no deductible, no insurance involvement
How to apply:
- Application form available on the NovoCare website
- Patient completes the financial section
- Provider completes the medical necessity section
- Submit by mail or fax through the prescribing office
- Uninsured patients who qualify are enrolled for 12 months; applicants within their state's Medicaid income limits must show a Medicaid denial first
The PAP is consistently underutilized. Many patients qualify but don't apply because they don't know it exists. If your monthly Wegovy cost is unsustainable and you're under the income threshold, ask your provider to start a PAP application.
What to do if you don't qualify for any program
If you're not eligible for the savings card (government insurance), not eligible for the PAP (income too high), and don't have commercial coverage, the realistic options are:
- Switch insurance during open enrollment. A commercial plan that covers Wegovy may be available through your employer or the marketplace.
- Push for coverage on your current plan. Many plans add or expand GLP-1 coverage year by year. A formal exception request, with documentation of medical necessity, is sometimes granted.
- Pivot to compounded semaglutide. Compounded semaglutide is not interchangeable with Wegovy but uses the same active molecule. Pricing across telehealth platforms ran $88 to $299 for month 1 (median $197) in the FormBlends price index on September 3, 2026, with no insurance involvement.
- Pay cash for Wegovy through NovoCare ($199 for the first two pen fills, then $349; pill $149 to $299 at September 2026 pricing).
- Switch to a different GLP-1. Some plans cover Saxenda or Zepbound but not Wegovy. Discuss with your prescriber.
The right path depends on what you can sustain financially long-term. GLP-1 weight loss is most effective when treatment continues for years, not months, so monthly cost matters more than total annual savings.
Internal links
- For background on Wegovy versus other GLP-1s, see /articles/general-glp1/wegovy-vs-zepbound/
- For overall GLP-1 cost strategies, see /articles/cost-and-insurance/glp1-cost-strategies/
- For details on compounded semaglutide, see /articles/glp1-hub/compounded-semaglutide-for-weight-loss-complete-guide-2026
The 2026 savings offer terms, verbatim: $25 floor, $100 monthly cap, $300 per 3-month fill
NovoCare's eligibility page, read September 4, 2026, states the terms in one sentence: pay as little as $25, subject to a maximum savings of $100 per 1-month prescription, $200 per 2-month prescription, or $300 per 3-month prescription. The offer applies to the Wegovy pen (0.25 mg to 2.4 mg), Wegovy HD (7.2 mg) and the Wegovy pill (1.5, 4, 9 and 25 mg), for patients with commercial insurance that covers Wegovy. Government beneficiaries are excluded. Earlier versions of this article described a $0 floor and unspecified caps; those terms are gone.
| Plan copay | Fill length | Novo pays | You pay |
|---|---|---|---|
| $50 | 1 month | $25 | $25 |
| $100 | 1 month | $75 | $25 |
| $125 | 1 month | $100 | $25 |
| $250 | 1 month | $100 | $150 |
| $450 | 3 months | $300 | $150 ($50 a month) |
| $750 | 3 months | $300 | $450 ($150 a month) |
A 3-month prescription is the quiet win in these terms: the cap triples but many plans charge less than three single copays for a 90-day fill, so ask your prescriber for a 90-day script once your dose is stable.
Coupon vs Novo self-pay: pick the lower number (dated table)
The card and Novo's self-pay program cannot be combined, so the question is which is lower for you. Self-pay prices below are from the NovoCare Price Guide (April 2026), confirmed on wegovy.com September 4, 2026; GoodRx notes the $199 intro price is for new self-pay patients with no Wegovy fill in the prior 365 days.
| Product | Self-pay price | Card is cheaper when your copay is | Self-pay is cheaper when your copay is |
|---|---|---|---|
| Wegovy pen, first two fills (new patients, through December 31, 2026) | $199 | Under $299 | $299 or more |
| Wegovy pen, ongoing (0.25 to 2.4 mg) | $349 | Under $449 | $449 or more |
| Wegovy HD 7.2 mg | $399 | Under $499 | $499 or more |
| Wegovy pill 1.5 mg | $149 | Under $249 | $249 or more |
| Wegovy pill 4 mg | $199 (the $149 offer ended August 31, 2026) | Under $299 | $299 or more |
| Wegovy pill 9 mg and 25 mg | $299 | Under $399 | $399 or more |
The rule of thumb: card price equals your copay minus $100 (floor $25). If that number is above the self-pay price for your product, pay self-pay. Self-pay purchases file no claim, so they do not count toward your deductible.
Medicare patients: the $50 GLP-1 Bridge replaces "no coupon for you"
The section above on government-insured patients is still right about the card: the Anti-Kickback Statute keeps Medicare patients off it. But since July 1, 2026 Medicare patients with obesity have something better. Through the Medicare GLP-1 Bridge, a CMS Innovation Center model running through December 31, 2027, eligible Part D beneficiaries pay $50 a month for any strength of the Wegovy pen or pill (and for the Zepbound KwikPen or Foundayo). The Part D deductible does not apply, the $50 does not count toward the beneficiary's out-of-pocket total, and prior authorization goes through a single central processor. CMS criteria: age 18 or older with a BMI of 35 or higher; or a BMI of 30 or higher with heart failure, uncontrolled hypertension despite two antihypertensive medications, or chronic kidney disease stage 3a or above; or a BMI of 27 or higher with pre-diabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease, with BMI judged at the time GLP-1 therapy was started. Novo's savings-offer page now states the Bridge price alongside the commercial card. If you are on Medicare, ask your prescriber about the Bridge before you consider self-pay or compounded.
Patient assistance income limits for 2026 (HHS guidelines)
The PAP section above used 2024 poverty figures. NovoCare's 2026 PAP rules: uninsured patients qualify at or below 400 percent of the federal poverty level (200 percent for Ozempic); uninsured applicants within their state's Medicaid income limits must show a Medicaid denial; uninsured patients are enrolled for 12 months; Medicare beneficiaries with drug coverage are no longer eligible for Ozempic through the PAP, and Part D patients may apply after October 15, 2026 for 2027. Using the 2026 HHS poverty guidelines ($15,960 for one person, plus $5,680 per additional person in the 48 contiguous states and D.C.):
| Household size | 400 percent of the 2026 poverty level |
|---|---|
| 1 | $63,840 |
| 2 | $86,560 |
| 3 | $109,280 |
| 4 | $132,000 |
One caution repeated from above: the PAP page we read did not name Wegovy among its products. Confirm Wegovy is on the current list before you and your prescriber spend time on the application.
What changes January 1, 2027: the $675 list price
Novo Nordisk announced on February 24, 2026 that Wegovy (pen and pill), Ozempic and Rybelsus will carry a $675 monthly list price from January 1, 2027, down from about $1,350 for Wegovy (CNBC). The card's terms are the same either way, but the math underneath changes for insured patients on coinsurance: 30 percent of $675 is $203, and $203 minus the $100 card benefit is $103, against $305 today. Patients inside a deductible also reach it more slowly, since each fill counts for less. Self-pay patients, who already pay $149 to $349, and Bridge patients at $50 see no direct change.
FAQ
How much does the Wegovy manufacturer coupon save?
For commercially insured patients whose plan covers Wegovy, the savings card reduces your copay by up to $100 per month, to a floor of $25. A $125 copay becomes $25; a $250 copay becomes $150. Patients with high copays should compare the result with Novo's $349 self-pay pen price.
Can I use the Wegovy savings card with Medicare?
No. Federal law prohibits manufacturer copay coupons from being used with Medicare, Medicaid, TRICARE, VA, or any government health program, and pharmacies must reject the card when government insurance is involved. Since July 1, 2026, however, eligible Medicare Part D patients can get any Wegovy pen or pill strength for $50 a month through the Medicare GLP-1 Bridge, with prior authorization.
What if my insurance doesn't cover Wegovy?
The savings card can't help if your plan doesn't cover Wegovy at all. The card reduces a copay; it doesn't create coverage. Options include: requesting a formulary exception, switching to a covered GLP-1, paying Novo's self-pay price ($199 for the first two pen fills, then $349; pill $149 to $299), applying for the patient assistance program, or pivoting to compounded semaglutide.
Where do I get the Wegovy savings card?
Through NovoCare.com/Wegovy or the dedicated savings card page on Novo Nordisk's website. Fill in basic information and receive a digital card. You can print it or save it to your phone. Bring it with your insurance card to the pharmacy.
How long can I use the Wegovy savings card?
Novo's current terms set per-fill caps ($100 per month, $300 per 3-month fill) rather than a months-of-use limit. Card terms have changed over time, so check the current Novo Nordisk program terms when you enroll.
Is the Wegovy cash-pay program the same as the savings card?
No. The self-pay program ($199 for the first two pen fills, then $349, or $149 to $299 for the pill) is a separate, direct-to-consumer pricing program for patients without insurance or whose insurance doesn't cover Wegovy. The savings card is a copay reducer for patients with commercial coverage. You cannot combine the two.
Can I use the Wegovy savings card if I'm in a marketplace plan?
Yes, marketplace plans (Healthcare.gov, state exchanges) are commercial plans for the purpose of the savings card. The card works the same as with employer or individual commercial coverage, as long as your specific plan covers Wegovy.
Does the Wegovy coupon work at all pharmacies?
At most major U.S. retail pharmacy chains (Walmart, CVS, Walgreens, Rite Aid, Costco, Sam's Club). Some independent pharmacies may not have the card processing set up. Mail-order pharmacies typically support the card. If a pharmacy says the card won't process, call the NovoCare helpline.
What's the patient assistance program for Wegovy?
The Novo Nordisk Patient Assistance Program (PAP) provides Novo medicines at no cost to uninsured patients with household income at or below 400% of the federal poverty level ($63,840 for one person in 2026). Apply through your provider via the NovoCare website, and confirm Wegovy is on the current product list first.
Can I use the savings card and a GoodRx coupon together?
No. GoodRx coupons replace insurance pricing, while the manufacturer savings card layers on top of insurance pricing. You have to choose one or the other. Compare the two prices and use whichever is lower at your pharmacy.
Why does the pharmacy say my coupon isn't going through?
Most common reasons: government insurance is being detected (correct rejection), prior authorization is not yet approved, the savings card is past its annual benefit cap, or the pharmacy's processing system hasn't updated. Call the NovoCare helpline printed on the card to troubleshoot.
Does the savings card cover prior authorization paperwork?
No. Prior authorization is between your prescriber and your insurance company. The savings card only reduces the copay after coverage is approved. If your PA is denied, the card has nothing to apply to.
How do I use a Wegovy manufacturer coupon at the pharmacy?
Enroll on novocare.com to get a digital card with a BIN, PCN, group and member ID. Hand the pharmacist your insurance card first and the savings card second; the plan sets your copay and the card then pays up to $100 of it, leaving you $25 or more. If it rejects, the usual causes are government insurance (a correct rejection), an unapproved prior authorization, or a plan that does not cover Wegovy at all.
How much is Wegovy with the manufacturer coupon?
As little as $25 a month if your commercial plan covers Wegovy and your copay is $125 or less; otherwise your copay minus $100, per NovoCare's terms read September 4, 2026. A $250 copay becomes $150 and a $450 copay becomes $350, at which point Novo's $349 self-pay pen price or the $149 to $299 pill is the better route. Three-month fills carry a $300 cap.
Is there a Wegovy manufacturer coupon if I have no insurance?
No. The savings card only reduces a copay from commercial insurance. Uninsured patients use Novo's self-pay program instead: $199 a month for the first two pen fills for new patients through December 31, 2026, then $349, or $149 to $299 for the Wegovy pill, at NovoCare Pharmacy or a participating retail pharmacy via GoodRx. Low-income uninsured patients can check the Patient Assistance Program.
Related guides
- Wegovy Coupon in 2026: How the Savings Card Works, Who Qualifies, and What You'll Pay
- Zepbound Coupon 2026: How the Lilly Savings Card Works, Who Qualifies, and What You'll Actually Pay
- Ozempic Coupon in 2026: How the Savings Card Works, Who Qualifies, and What You'll Pay
- Zepbound Coupon 2025: How the Savings Card Works, Who Qualifies, and What You'll Actually Pay
- The Zepbound Manufacturer Coupon Explained: Who Qualifies, How Much You Save, and How to Use It at the Pharmacy
- Ozempic Manufacturer Coupon in 2026: Who Qualifies, How Much You Save, and What to Do If You Don't
- Tool: cost calculator
Sources
- Novo Nordisk. Wegovy savings offer terms. NovoCare. 2026.
- Novo Nordisk. Patient Assistance Program for Wegovy. NovoCare. 2026.
- U.S. Department of Health and Human Services, Office of Inspector General. Advisory opinion on manufacturer copay assistance programs.
- Federal Anti-Kickback Statute. 42 U.S.C. § 1320a-7b(b).
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384:989-1002.
- American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment. Diabetes Care. 2024;47(Suppl 1):S158-S178.
- Centers for Medicare and Medicaid Services. Part D drug coverage and prior authorization. 2024.
- Novo Nordisk. Wegovy direct cash-pay program announcement and pricing updates. 2024-2026.
- Federal Poverty Level guidelines. U.S. Department of Health and Human Services. 2026.
- Novo Nordisk (NovoCare). Wegovy Savings Card eligibility and terms, read September 4, 2026. https://www.novocare.com/eligibility/wegovy-savings-card.html
- Novo Nordisk (NovoCare). Wegovy savings offer page, read September 4, 2026. https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
- Novo Nordisk (NovoCare). Wegovy Price Guide, US26NC00049, April 2026. https://www.novocare.com/content/dam/novonordisk/novocare/redesign/pdf/Wegovy_Price_Guide.pdf
- Novo Nordisk. What to pay for Wegovy, self-pay and savings offer pricing, read September 4, 2026. https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html
- GoodRx. Wegovy prices and self-pay offer, read September 4, 2026. https://www.goodrx.com/wegovy
- Novo Nordisk (NovoCare). Patient Assistance Program eligibility for 2026, read September 4, 2026. https://www.novocare.com/diabetes/help-with-costs/pap.html
- U.S. Department of Health and Human Services, ASPE. 2026 poverty guidelines. https://aspe.hhs.gov/poverty-guidelines
- Centers for Medicare and Medicaid Services. Medicare GLP-1 Bridge model overview, read September 4, 2026. https://www.cms.gov/priorities/innovation/innovation-models/medicare-glp-1-bridge
- Centers for Medicare and Medicaid Services. Medicare GLP-1 Bridge: information for providers, page last modified August 6, 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
- CNBC. Novo Nordisk to slash Wegovy, Ozempic U.S. list prices by up to 50 percent, February 24, 2026. https://www.cnbc.com/2026/02/24/novo-nordisk-to-slash-wegovy-ozempic-us-list-prices-by-up-to-50percent.html
- FormBlends Research. Compounded GLP-1 Price Index, as of September 3, 2026. https://formblends.com/feeds/glp1-prices.json
Footer disclaimers (all 4 verbatim)
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Wegovy, Ozempic, Saxenda, and NovoCare are registered trademarks of Novo Nordisk A/S. Zepbound is a registered trademark of Eli Lilly and Company. Walmart, CVS, Walgreens, Costco, GoodRx, and TRICARE are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →